Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting cushmanwakefield.com to read:%0A%0A {0} %0A%0A {1}

Georgia: An Emerging Market for Life Sciences

Chad Koenig • 7/27/2022

Georgia has enormous potential as a life science market, and the state has emerged in recent years as a leader for life science opportunities. The state’s business-friendly climate, lauded higher education system, and highly-educated and diverse workforce lay the groundwork for future growth. Georgia is home to more than 2,000 life science and global health organizations and R&D leaders, including the U.S. Center for Disease Control & Prevention.

A thriving network of business incubators and research institutions provides support for both life science startups and existing companies seeking to grow their operations in Georgia. In fact, Georgia life science companies raised more venture capital in 2021 than any year in history with a total of $255.85M. National Institute of Health funding has also been strong: since the start of 2021, Georgia institutions have been awarded $1.13B in NIH funding. With $418.7M awarded through early June, the 2022 total could yield the state’s highest ever year of funding.

Georgia’s graduates are also trained in the nation’s top research-intensive institutions, and the state ranks among the top in the nation for concentration of life science graduates. More than 33,000 life science-related degrees were awarded by post-secondary institutions between 2016-2020. Georgia Tech and Emory University’s joint biomedical engineering/bioengineering program ranks No. 3 in the nation. Other institutions offering extensive bioscience programs include The University of Georgia, Georgia State University, Clark Atlanta University, Mercer University, Augusta University, and the Morehouse School of Medicine.

Within Georgia, Atlanta is becoming a more attractive market due to the city’s more affordable cost of labor and real estate compared to other “life science” gateway cities. The city is also a top 10 GDP city in the United States. These characteristics no longer make Atlanta a gamble for life science companies interested in growing within the market. 

Industry leaders Boston Scientific and Moderna have already made announcements about their growth plans in Atlanta this year, serving as a proof point of the viability of the market for life science. The caveat is that life science companies have space needs that go well above the typical office user build out, so ensuring there is the proper infrastructure and support where they invest in new space is critical. 

In the past, lack of available lab space, outside of a university or corporate campus, has been a negative for Atlanta. The market, however, has responded to the changing space needs for the life science sector. Science Square and The Center for Global Health Innovation are two exciting projects with space coming into the pipeline later this year and all the way into early 2024. The added space with allow Atlanta to support the worthwhile investment being made in the life science sector and its future expansion throughout the city.  

Download the full report to learn more.

 
Insights in your Inbox
Subscribe to the latest local market research, insights and analysis from Cushman & Wakefield across the United States.
Subscribe

Related Insights

22q1-lifesciencesupdate-card
Research • Lab

2022: Life Sciences North American Update

The life sciences industry has been on the rise over the past half-decade thanks to a surge in new products and technology, as well as an influx of capital from both public and private investors.
David Smith • 3/17/2022
globe outlook investment
Insights • Economy

Webinar | Nearing the Other Side of the Pandemic: What’s Next?

Join Chief Economist Kevin Thorpe and our global research leaders as they discuss key themes and share their outlook for the economy and for the commercial real estate industry around the world in 2022 and beyond.
2/4/2022

Ready to talk?

Our professionals are ready to provide further details on this and many other topics.

With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on  Cookies

More Options
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All
SAVE SETTINGS